Open AccessSynergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii
Author(s) -
Jiaqi Cheng,
Jun Yan,
Zeferino Reyna,
Matt Slarve,
Peggy Lu,
Brad Spellberg,
Brian Luna
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02204-20
Subject(s) - rifabutin , colistin , acinetobacter baumannii , microbiology and biotechnology , antibiotics , medicine , drug resistance , biology , bacteria , genetics , pseudomonas aeruginosa , clarithromycin
Recently, we reported rifabutin hyperactivity against Acinetobacter baumannii We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic in vitro and in vivo , and low-dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant A. baumannii infections.